• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种针对高级别T1期膀胱癌管理的风险分层方法。

A risk-stratified approach to the management of high-grade T1 bladder cancer.

作者信息

Mannas Miles P, Lee Taeweon, Nykopp Timo K, Batista da Costa Jose, Black Peter C

机构信息

Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.

出版信息

Curr Opin Urol. 2018 Nov;28(6):563-569. doi: 10.1097/MOU.0000000000000548.

DOI:10.1097/MOU.0000000000000548
PMID:30148753
Abstract

PURPOSE OF REVIEW

A bladder-preserving approach for high-grade nonmuscle invasive bladder cancer that has invaded the lamina propria (T1HG) may result in increased recurrence, progression, and even death from bladder cancer in some patients. Initial radical cystectomy does have increased cancer-specific survival (CSS), but represents significant overtreatment for many patients. An evidence-based, risk-stratified approach is required to select patients for immediate radical cystectomy in order to improve CSS.

RECENT FINDINGS

A restaging transurethral resection aids in optimal staging and treatment of T1HG. Intravesical Bacillus Calmette-Guerin induction followed by 3 years of maintenance is the standard adjuvant management. However, when very high-risk (hydronephrosis, abnormal bimanual examination, variant histology, lymphovascular invasion, or residual disease on re-resection, and Bacillus Calmette-Guerin failure or early recurrence) or multiple high-risk factors (concomitant CIS, size >3 cm, multifocality, unfavorable tumor location, extensive lamina propria invasion, and elderly) are present, the risk of progression often outweighs the risk associated with radical cystectomy. In these cases, an immediate radical cystectomy likely provides an improved opportunity for cure compared to a bladder-preserving strategy.

SUMMARY

In order to increase the CSS of patients diagnosed with T1HG bladder cancer, an aggressive approach may benefit those with increased risk of progression.

摘要

综述目的

对于侵犯固有层的高级别非肌层浸润性膀胱癌(T1HG)采用保留膀胱的方法,可能会导致部分患者膀胱癌复发、进展甚至死亡风险增加。初始根治性膀胱切除术确实能提高癌症特异性生存率(CSS),但对许多患者而言属于过度治疗。需要一种基于证据的、风险分层的方法来选择适合立即进行根治性膀胱切除术的患者,以提高CSS。

最新研究发现

再次经尿道膀胱肿瘤切除术有助于对T1HG进行最佳分期和治疗。膀胱内卡介苗诱导治疗后维持3年是标准的辅助治疗方法。然而,当存在极高风险因素(肾积水、双合诊异常、组织学变异、淋巴管浸润、再次切除时存在残留病灶以及卡介苗治疗失败或早期复发)或多个高风险因素(合并原位癌、肿瘤大小>3 cm、多灶性、肿瘤位置不佳、固有层广泛浸润以及老年患者)时,进展风险往往超过根治性膀胱切除术的相关风险。在这些情况下,与保留膀胱策略相比,立即进行根治性膀胱切除术可能为治愈提供更好的机会。

总结

为了提高T1HG膀胱癌患者的CSS,积极的治疗方法可能会使进展风险增加的患者受益。

相似文献

1
A risk-stratified approach to the management of high-grade T1 bladder cancer.一种针对高级别T1期膀胱癌管理的风险分层方法。
Curr Opin Urol. 2018 Nov;28(6):563-569. doi: 10.1097/MOU.0000000000000548.
2
Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.初诊 T1 高级别膀胱尿路上皮癌的治疗策略:新见解和更新建议。
Eur Urol. 2018 Nov;74(5):597-608. doi: 10.1016/j.eururo.2018.06.024. Epub 2018 Jul 13.
3
Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.经尿道治疗非肌肉浸润性膀胱癌:系统评价和荟萃分析。
J Urol. 2017 May;197(5):1189-1199. doi: 10.1016/j.juro.2016.12.090. Epub 2016 Dec 24.
4
An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer.对新诊断的高级别 T1(以前为 T1G3)膀胱癌的治疗策略进行的最新批判性分析。
Eur Urol. 2010 Jan;57(1):60-70. doi: 10.1016/j.eururo.2009.08.024. Epub 2009 Sep 1.
5
Management of high-risk non-muscle invasive bladder cancer.高危非肌层浸润性膀胱癌的管理
Minerva Urol Nefrol. 2012 Dec;64(4):255-60.
6
The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis.卡介苗失败后根治性膀胱切除术的时机:结局比较和预后危险因素分析。
J Urol. 2016 Jun;195(6):1704-9. doi: 10.1016/j.juro.2016.01.087. Epub 2016 Jan 22.
7
Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.高危Ta、T1期膀胱癌诱导使用卡介苗后的复发模式及预后
J Urol. 2007 May;177(5):1727-31. doi: 10.1016/j.juro.2007.01.031.
8
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.再次经尿道膀胱肿瘤切除术(re-cTURBT)作为pT1期高级别(HG)疾病复发和进展的风险指标是否有用?一项单中心经验。
Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272.
9
Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.卡介苗诱导治疗后首次评估时膀胱癌的乳头状复发:对临床试验设计的启示
Eur Urol. 2016 Nov;70(5):778-785. doi: 10.1016/j.eururo.2016.02.031. Epub 2016 Feb 24.
10
Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.根据日本登记膀胱癌患者的数据得出的Ta、T1期非肌层浸润性膀胱癌肿瘤复发的临床结果:日本泌尿外科学会1999 - 2001年报告
Int J Urol. 2009 Mar;16(3):279-86. doi: 10.1111/j.1442-2042.2008.02235.x. Epub 2009 Jan 20.

引用本文的文献

1
T1 bladder carcinoma with variant histology: pathological features and clinical significance.T1 膀胱移行细胞癌伴变异型组织学:病理特征和临床意义。
Virchows Arch. 2022 May;480(5):989-998. doi: 10.1007/s00428-021-03264-6. Epub 2022 Feb 4.